a potent small-molecule TNIK previously developed by Insilico Medicine, which has already advanced into clinical trials for idiopathic pulmonary fibrosis (IPF)-as a highly effective senomorphic ...

For the first time, a new paper in Nature Biotechnology discloses the raw experimental data and the preclinical and clinical evaluation of Insilico Medicine's potentially first-in-class TNIK ...

which analyzed vast omics and clinical datasets to identify TNIK (TRAF2 and NCK-interacting kinase) as a promising novel target for IPF. Building on this discovery, researchers used Chemistry42 ...